Figure 1
From: A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer
Illustrates IL-6 release in the whole-blood cytokine assay. Samples were taken at set time points during therapy (pretreatment, 24 h, days 15 and 28). IL-6 was measured by ELISA. A rise in IL-6 levels was seen in two patients (patients 1 and 4) after 24 h of bryostatin-1. After 28 days therapy, the production of IL-6 was reduced in all the six patients (P=0.03).
